Interim health related quality of life (QoL) from LAPACT, a Phase 2 trial of nab-paclitaxel (nab-P) plus gemcitabine (G) for patients (Pts) with locally advanced pancreatic cancer (LAPC)

被引：0
|
作者：
Portales, F. [1 ]
Philip, P. A. [2 ]
Hammel, P. [3 ]
Buscaglia, M. [4 ]
Pazo-Cid, R. [5 ]
Manzano Mozo, J. L. [6 ]
Kim, E. S. [7 ]
Dowden, S. [8 ]
Zakari, A. [9 ]
Borg, C. [10 ]
Terrebonne, E. [11 ]
Rivera Herrero, F. [12 ]
Li, J. Shiansong [13 ]
Ong, T. J. [14 ]
Nydam, T. [14 ]
Lacy, J. [15 ]
机构：
[1] Inst Reg Canc Montpellier ICM, Digestif, Montpellier, France
[2] Karmanos Canc Inst, Dept Oncol, Detroit, MI USA
[3] Hop Beaujon, Gastroenterol, Clichy, France
[4] Azienda Osped Univ San Martino, Med Oncol, Genoa, Italy
[5] Hosp Miguel Servet, Med Oncol, Zaragoza, Spain
[6] Hosp Badalona Germans Trias & Pujol, Med Oncol, Barcelona, Spain
[7] Levine Canc Inst, Med Oncol, Charlotte, NC USA
[8] Tom Baker Canc Clin, Med Oncol, Calgary, AB, Canada
[9] Florida Hosp Canc Inst, Gastro Intestinal Canc Program, Orlando, FL USA
[10] Ctr Hosp Belfort Montbeliard, Med Oncol, Montbeliard, France
[11] Hosp Haut Leveque, Med Oncol, Giround, France
[12] Hosp Univ Marques de Valdecilla, Med Oncol, Santander, Spain
[13] Celgene Corp, Biostat, Summit, NJ USA
[14] Celgene Corp USA, Med Affairs, Summit, NJ USA
[15] Yale Canc Ctr, Med Oncol, New Haven, CT USA
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
730P
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Gemcitabine plus nab-paclitaxel for locally advanced or borderline resectable pancreatic cancer
    Akiko Tsujimoto
    Kentaro Sudo
    Kazuyoshi Nakamura
    Emiri Kita
    Ryusuke Hara
    Wataru Takayama
    Hiroshi Ishii
    Taketo Yamaguchi
    Scientific Reports, 9
  • [32] Impact of adjuvant treatment with nab-paclitaxel and gemcitabine (nab-P plus GEM) vs gemcitabine alone (GEM) on health-related quality of life (QoL) in patients (pts) with surgically resected pancreatic adenocarcinoma (PA) in the adjuvant pancreatic adenocarcinoma clinical trial (APACT)
    Riess, H.
    Braverman, J.
    Reni, M.
    Dueck, A. C.
    Hendifar, A.
    Oh, D-Y.
    Li, C-P.
    Macarulla Mercade, T.
    Shah, A.
    Joshi, N.
    Botterman, M.
    Mantovani, E.
    Lu, B.
    Tempero, M. A.
    ANNALS OF ONCOLOGY, 2019, 30
  • [33] Analysis of prognostic factors in advanced pancreatic cancer (APDAC) patients (pts) undergoing to first-line nab-paclitaxel (Nab-P) and gemcitabine (G) treatment
    Giordano, Guido
    Vaccaro, Vanja
    Lucchini, Eleonora
    Bertocchi, Paola
    Bergamo, Francesca
    Musettini, Gianna
    Santoni, Matteo
    Lo Re, Giovanni
    Giommoni, Elisa
    Russano, Marco
    Campidoglio, Serena
    Santini, Daniele
    Vasile, Enrico
    Cascinu, Stefano
    Zagonel, Vittorina
    Zaniboni, Alberto
    Melisi, Davide
    Milella, Michele
    Febbraro, Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [34] Nab-paclitaxel (Nab-P) and gemcitabine (G) as first-line chemotherapy (CT) in advanced pancreatic cancer (APDAC) elderly patients (pts): A "real-life" study
    Giordano, Guido
    Vaccaro, Vanja
    Lucchini, Eleonora
    Musettini, Gianna
    Bertocchi, Paola
    Bergamo, Francesca
    Giommoni, Elisa
    Santoni, Matteo
    Russano, Marco
    Campidoglio, Serena
    Santini, Daniele
    Zaniboni, Alberto
    Zagonel, Vittorina
    Cascinu, Stefano
    Vasile, Enrico
    Melisi, Davide
    Milella, Michele
    Febbraro, Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [35] Reinitiating nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer
    Borazanci, Erkut
    Schroeder, Katy
    Jameson, Gayle S.
    Ramanathan, Ramesh K.
    Von Hoff, Daniel D.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [36] Prognostic factors (PFs) of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients (pts) with metastatic pancreatic cancer (MPC).
    Moore, Malcolm J.
    Von Hoff, Daniel D.
    Ervin, Thomas J.
    Arena, Francis P.
    Chiorean, E. Gabriela
    Infante, Jeffrey R.
    Hon, Jeremy K.
    Biakhov, Mikhail Yu
    Hingorani, Sunil R.
    Ganju, Vinod
    Weekes, Colin D.
    Scheithauer, Werner
    Ramanathan, Ramesh K.
    Tabernero, Josep
    Goldstein, David
    Wei, Xinyu
    Romano, Alfredo
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [37] Nab Paclitaxel (Nab-P) and Gemcitabine (G) as first line chemotherapy (CT) in advanced pancreatic cancer (APDAC) patients (pts): An Italian "real life" study
    Giordano, G.
    Febbraro, A.
    Vaccaro, V.
    Zagonel, V.
    De Giorgi, U.
    Melisi, D.
    Vasile, E.
    Bianco, R.
    Lo Re, G.
    Valente, M.
    Formica, V.
    Montesarchio, V.
    Maiorino, L.
    Sanna, G.
    Bittoni, A.
    Ricci, V.
    Santini, D.
    Zaniboni, A.
    Milella, M.
    De Vita, F.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S444 - S444
  • [38] APACT: Phase III randomized trial of adjuvant treatment with nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem alone in patients (pts) with resected pancreatic cancer (PC).
    Tempero, Margaret A.
    Cardin, Dana Backlund
    Goldstein, David
    O'Reilly, Eileen Mary
    Philip, Agop Philip
    Riess, Hanno
    Macarulla, Teresa
    Yung, Lotus
    Li, Mingyu
    Lu, Brian D.
    Biankin, Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [39] A phase I and randomized phase II trial to evaluate the efficacy and safety of nab-paclitaxel (nab-P) in combination with gemcitabine (G) for the treatment of patients with ECOG 2 advanced pancreatic cancer (PDAC)
    Hidalgo, M.
    Pazo-Cid, R.
    Guillen-Ponce, C.
    Lopez, R.
    Vera, R.
    Reboredo, M.
    Munoz, A.
    Martinez de Castro, E.
    Diaz Beveridge, R.
    La Casta, A.
    Martin-Valades, J. I.
    Cubillo, A.
    Martinez-Galan, J.
    Ales, I.
    Sastre, J.
    Macarulla Mercade, T.
    ANNALS OF ONCOLOGY, 2017, 28
  • [40] Combination nab-paclitaxel (Nab-P) plus gemcitabine (G) as first-line treatment in advanced pancreatic cancer (APC): Our experience.
    De Vita, Fernando
    Orditura, Michele
    Febbraro, Antonio
    Morgillo, Floriana
    Laterza, Maria Maddalena
    Fabozzl, Alesslo
    Giordano, Guido
    Savastano, Beatrice
    Petrillo, Angelica
    Ventriglia, Joie
    Ciardiello, Fortunato
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345